<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40950471</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>03</Day></PubDate></JournalIssue><Title>medRxiv : the preprint server for health sciences</Title><ISOAbbreviation>medRxiv</ISOAbbreviation></Journal><ArticleTitle>Sodium-Glucose Cotransporter 2 Inhibitors for Lithium-Associated Kidney Dysfunction in Mood Disorders: A Real-World Historical Cohort Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2025.09.02.25334914</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2025.09.02.25334914</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Sodium-glucose cotransporter-2 inhibitors (SGLT2i), initially developed for type 2 diabetes, have shown promise in improving renal outcomes in patients with and without diabetes. However, their effect on lithium-associated kidney dysfunction remains unknown.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This historical cohort study included patients from Mayo Clinic (2001-2023) with mood disorders who received lithium for &#x2265;6 months and later used SGLT2i for &#x2265;1 month. Data on SGLT2i use and lithium treatment were extracted from electronic health records. Serum creatinine values were used to calculate estimated glomerular filtration rate (eGFR) trajectories. Linear mixed-effects models with piecewise linear splines were used to estimate eGFR slopes before and after SGLT2i initiation, adjusted for age and sex.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Fifty-six patients (mean age 57.4 years, 46.4% female), predominantly with bipolar disorder (86%), were included. The mean eGFR, measured nearest to SGLT2i initiation, was 77.9&#xb1;26.0 mL/min/1.73 m<sup>2</sup>, and the mean duration of SGLT2i use was 19.5&#xb1;17.8 months. Before SGLT2i initiation, eGFR declined at a rate of -1.43 mL/min/1.73 m<sup>2</sup> per year (p&lt;0.001). After initiation, eGFR increased by 0.69 mL/min/1.73 m<sup>2</sup> per year, reflecting a +2.13 change (p=0.025). Sensitivity analyses, including only patients on lithium at SGLT2i initiation (n=22) or who had &gt;1 year of SGLT2i use (n=29) showed similar, though non-significant, changes in slopes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">SGLT2i treatment was associated with a significant improvement in eGFR trajectory in patients with mood disorders who received long-term lithium therapy. These findings suggest a potential role for SGLT2is in mitigating lithium-associated kidney dysfunction and highlight the need for randomized controlled trials in this population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ercis</LastName><ForeName>Mete</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Psychology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarikogullari</LastName><ForeName>Idil</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Psychology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pazdernik</LastName><ForeName>Vanessa K</ForeName><Initials>VK</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez-Suarez</LastName><ForeName>Maria L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baweja</LastName><ForeName>Raman</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Health, Pennsylvania State College of Medicine, Hershey, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health Sciences, Pennsylvania State College of Medicine, Hershey, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miola</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Psychology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, University of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abulseoud</LastName><ForeName>Osama A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic Arizona, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Jonathan G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McElroy</LastName><ForeName>Susan L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Lindner Center of HOPE Research Institute, Mason, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuellar-Barboza</LastName><ForeName>Alfredo B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Psychology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Universidad Aut&#xf3;noma de Nuevo Le&#xf3;n, Monterrey, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gitlin</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozerdem</LastName><ForeName>Aysegul</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Psychology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frye</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Psychology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Balwinder</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-7062-8192</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Psychology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KL2 TR002379</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002377</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>medRxiv</MedlineTA><NlmUniqueID>101767986</NlmUniqueID></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar Disorder</Keyword><Keyword MajorTopicYN="N">Creatinine</Keyword><Keyword MajorTopicYN="N">Kidney</Keyword><Keyword MajorTopicYN="N">Lithium</Keyword><Keyword MajorTopicYN="N">Mood Disorders</Keyword><Keyword MajorTopicYN="N">Sodium-Glucose Transporter 2 Inhibitors</Keyword></KeywordList><CoiStatement>ME, IT, VKP, MLGS, AM, OAA, JGL, and MJG report no conflicts of interest. RB has received grant funding from Cardinal Health Foundation (Children&#x2019;s Hospital Association and Zero Suicide Initiative), research funding from Supernus and served on the advisory board for Ironshore. SLM has been a consultant to or a member of the scientific advisory boards of Axsome, Idorsia, Kallyope, Levo, Novo Nordisk, and Soleno. She has been a principal or co-investigator on studies sponsored by Axsome and the Marriott Foundation. She is also an inventor on United States Patent No. 6,323,236 B2, Use of Sulfamate Derivatives for Treating Impulse Control Disorders, and along with the patent&#x2019;s assignee, the University of Cincinnati, Cincinnati, Ohio, has received payments from Johnson &amp; Johnson, which has exclusive rights under the patent. ABCB has received lecture and consulting fees from Asofarma and Exeltis. AO received support from Mayo Clinic, Breakthrough Discoveries for thriving with Bipolar Disorder (BD2) and CME travel and honoraria from Carnot Laboratories. MAF has been a consultant to or member of the scientific advisory boards of Carnot Laboratories and American Physician Institute. He has been a principal or co-investigator on studies sponsored by Assurex Health, Baszucki Group, Breakthrough Discoveries for Thriving with Bipolar Disorder (BD2), and Mayo Foundation. He also has financial interest/stock ownership/royalties with Chymia LLC. BS has received research grant support from Mayo Clinic, the National Network of Depression Centers, Breakthrough Discoveries for Thriving with Bipolar Disorder and NIH. He is a KL2 Mentored Career Development Program scholar, supported by CTSA Grant Number KL2TR002379 from the NCATS. He has received honoraria (to Mayo Clinic) from Elsevier for editing a Clinical Overview on Treatment-Resistant Depression.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>7</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40950471</ArticleId><ArticleId IdType="pmc">PMC12425027</ArticleId><ArticleId IdType="doi">10.1101/2025.09.02.25334914</ArticleId><ArticleId IdType="pii">2025.09.02.25334914</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singh B, Swartz HA, Cuellar-Barboza AB, et al. Bipolar disorder. Lancet. Jul 22 2025;doi: 10.1016/S0140-6736(25)01140-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(25)01140-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. Mar 2018;20(2):97&#x2013;170. doi: 10.1111/bdi.12609</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bdi.12609</ArticleId><ArticleId IdType="pmc">PMC5947163</ArticleId><ArticleId IdType="pubmed">29536616</ArticleId></ArticleIdList></Reference><Reference><Citation>Ercis M, Ozerdem A, Singh B. When and How to Use Lithium Augmentation for Treating Major Depressive Disorder. J Clin Psychiatry. Mar 8 2023;84(2)doi: 10.4088/JCP.23ac14813</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.23ac14813</ArticleId></ArticleIdList></Reference><Reference><Citation>Ermis C, Taipale H, Tanskanen A, et al. Real-world effectiveness of pharmacological maintenance treatment of bipolar depression: a within-subject analysis in a Swedish nationwide cohort. Lancet Psychiatry. Mar 2025;12(3):198&#x2013;207. doi: 10.1016/s2215-0366(24)00411-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2215-0366(24)00411-5</ArticleId><ArticleId IdType="pubmed">39922213</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm M, Tanskanen A, L&#xe4;hteenvuo M, Tiihonen J, Taipale H. Comparative effectiveness of mood stabilizers and antipsychotics in the prevention of hospitalization after lithium discontinuation in bipolar disorder. Eur Neuropsychopharmacol. Aug 2022;61:36&#x2013;42. doi: 10.1016/j.euroneuro.2022.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2022.05.012</ArticleId><ArticleId IdType="pubmed">35763976</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoretsanitis G, de Filippis R, Brady BM, Homan P, Suppes T, Kane JM. Prevalence of impaired kidney function in patients with long-term lithium treatment: A systematic review and meta-analysis. Bipolar Disord. May 2022;24(3):264&#x2013;274. doi: 10.1111/bdi.13154</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bdi.13154</ArticleId><ArticleId IdType="pubmed">34783413</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgensen A, Sloth MMB, Larsen EN, Osler M, Kessing LV. Prescription sequences in bipolar disorder - A nationwide Danish register-based study of 19,927 individuals followed for 10 years. Eur Neuropsychopharmacol. Apr 2025;93:51&#x2013;57. doi: 10.1016/j.euroneuro.2025.01.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2025.01.008</ArticleId><ArticleId IdType="pubmed">39955809</ArticleId></ArticleIdList></Reference><Reference><Citation>Rybakowski JK. Lithium. Eur Neuropsychopharmacol. Apr 2022;57:86&#x2013;87. doi: 10.1016/j.euroneuro.2022.01.111</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2022.01.111</ArticleId><ArticleId IdType="pubmed">35189567</ArticleId></ArticleIdList></Reference><Reference><Citation>Ercis M, Gonzalez Suarez ML, Singh B. Lithium and Kidney Disease. Mayo Clin Proc. Jan 2025;100(1):19&#x2013;25. doi: 10.1016/j.mayocp.2024.10.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2024.10.008</ArticleId><ArticleId IdType="pmc">PMC11700745</ArticleId><ArticleId IdType="pubmed">39641712</ArticleId></ArticleIdList></Reference><Reference><Citation>Pahwa M, Joseph B, Nunez NA, et al. Long-term lithium therapy and risk of chronic kidney disease in bipolar disorder: A historical cohort study. Bipolar Disord. Nov 2021;23(7):715&#x2013;723. doi: 10.1111/bdi.13052</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bdi.13052</ArticleId><ArticleId IdType="pubmed">33548063</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis J, Desmond M, Berk M. Lithium and nephrotoxicity: a literature review of approaches to clinical management and risk stratification. BMC Nephrology. 2018/11/03 2018;19(1):305. doi: 10.1186/s12882-018-1101-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-018-1101-4</ArticleId><ArticleId IdType="pmc">PMC6215627</ArticleId><ArticleId IdType="pubmed">30390660</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsaik AK, Chaudhary A, Sharma S, Delgoffe BE, Gabor R, Singh B. Effects of long-term lithium therapy on kidney functioning in mood disorders: A population-based historical cohort study. Bipolar Disord. Feb 2025;27(1):28&#x2013;35. doi: 10.1111/bdi.13501</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bdi.13501</ArticleId><ArticleId IdType="pubmed">39279615</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan JKN, Solmi M, Correll CU, et al. Predicting 10-year risk of chronic kidney disease in lithium-treated patients with bipolar disorder: A risk model development and internal crossvalidation study. Eur Neuropsychopharmacol. Jun 2025;95:24&#x2013;30. doi: 10.1016/j.euroneuro.2025.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2025.03.008</ArticleId><ArticleId IdType="pubmed">40220570</ArticleId></ArticleIdList></Reference><Reference><Citation>Pahwa M, Singh B. Lithium therapy in patients with chronic kidney disease-A clinical dilemma? Eur Neuropsychopharmacol. May 2020;34:87. doi: 10.1016/j.euroneuro.2020.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2020.03.007</ArticleId><ArticleId IdType="pubmed">32245675</ArticleId></ArticleIdList></Reference><Reference><Citation>Werneke U, Ott M, Renberg ES, Taylor D, Stegmayr B. A decision analysis of long-term lithium treatment and the risk of renal failure. Acta Psychiatr Scand. Sep 2012;126(3):186&#x2013;97. doi: 10.1111/j.1600-0447.2012.01847.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0447.2012.01847.x</ArticleId><ArticleId IdType="pmc">PMC3440572</ArticleId><ArticleId IdType="pubmed">22404233</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoot TS, Molmans THJ, Grootens KP, Kerckhoffs APM. Systematic review and practical guideline for the prevention and management of the renal side effects of lithium therapy. Eur Neuropsychopharmacol. Feb 2020;31:16&#x2013;32. doi: 10.1016/j.euroneuro.2019.11.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2019.11.006</ArticleId><ArticleId IdType="pubmed">31837914</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoekstra R, Lekkerkerker MN, Kuijper TM, Bosch TM, van Alphen AM. Renal function after withdrawal of lithium. Bipolar Disord. Sep 2022;24(6):667&#x2013;670. doi: 10.1111/bdi.13178</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bdi.13178</ArticleId><ArticleId IdType="pubmed">35075735</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitlin M. Lithium and long-term renal effects: A complex clinical concern. Bipolar Disord. Aug 8 2023;doi: 10.1111/bdi.13374</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bdi.13374</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao EC, Henry RR. SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov. Jul 2010;9(7):551&#x2013;9. doi: 10.1038/nrd3180</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3180</ArticleId><ArticleId IdType="pubmed">20508640</ArticleId></ArticleIdList></Reference><Reference><Citation>Heerspink HL, Stef&#xe1;nsson B, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine (NEJM). 2020;383(15):1436&#x2013;1446. doi: 10.1056/NEJMoa2024816</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2024816</ArticleId><ArticleId IdType="pubmed">32970396</ArticleId></ArticleIdList></Reference><Reference><Citation>Mende C. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape. Advances in Therapy. 2021;39(1):148&#x2013;164. doi: 10.1007/s12325-021-01994-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-021-01994-2</ArticleId><ArticleId IdType="pmc">PMC8799531</ArticleId><ArticleId IdType="pubmed">34846711</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. Jan 12 2023;388(2):117&#x2013;127. doi: 10.1056/NEJMoa2204233</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204233</ArticleId><ArticleId IdType="pmc">PMC7614055</ArticleId><ArticleId IdType="pubmed">36331190</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkovic V, Jardine M, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine (NEJM). 2019;380(24):2295&#x2013;2306. doi: 10.1056/NEJMoa1811744</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1811744</ArticleId><ArticleId IdType="pubmed">30990260</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiazzi BF, Piccoli GF, Wayerbacher LF, et al. SGLT2 inhibitors and kidney outcomes across the spectrum of kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. Sep 16 2024;doi: 10.2215/cjn.0000000000000568</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/cjn.0000000000000568</ArticleId></ArticleIdList></Reference><Reference><Citation>Vart P, Jongs N, Wheeler D, Heerspink HL, Langkilde A, Chertow G. Effectiveness and Safety of Dapagliflozin for Black and White Patients With Chronic Kidney Disease in North and South America. JAMA Network Open. 2023;6(4):e2310877-undefined. doi: 10.1001/jamanetworkopen.2023.10877</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.10877</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi T, Smyth B, Di Tanna G, et al. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. American Journal of Kidney Diseases. 2023;82(1):84&#x2013;96.e1. doi: 10.1053/j.ajkd.2022.12.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2022.12.015</ArticleId><ArticleId IdType="pubmed">36889425</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFronzo R, Reeves WB, Awad A. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nature Reviews Nephrology. 2021;17(5):319&#x2013;334. doi: 10.1038/s41581-021-00393-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-021-00393-8</ArticleId><ArticleId IdType="pubmed">33547417</ArticleId></ArticleIdList></Reference><Reference><Citation>Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. Nov 4 2021;385(19):1737&#x2013;1749. doi: 10.1056/NEJMoa2102953</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2102953</ArticleId><ArticleId IdType="pmc">PMC8822996</ArticleId><ArticleId IdType="pubmed">34554658</ArticleId></ArticleIdList></Reference><Reference><Citation>Inker LA, Heerspink HJL, Tighiouart H, et al. GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. J Am Soc Nephrol. Sep 2019;30(9):1735&#x2013;1745. doi: 10.1681/asn.2019010007</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/asn.2019010007</ArticleId><ArticleId IdType="pmc">PMC6727261</ArticleId><ArticleId IdType="pubmed">31292197</ArticleId></ArticleIdList></Reference><Reference><Citation>Fransson F, Werneke U, &#xd6;hlund L, Jonsson PA, Ott M. Kidney function decline improves after lithium discontinuation. J Intern Med. Jan 20 2025;doi: 10.1111/joim.20054</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.20054</ArticleId></ArticleIdList></Reference><Reference><Citation>Elhakeem A, Hughes RA, Tilling K, et al. Using linear and natural cubic splines, SITAR, and latent trajectory models to characterise nonlinear longitudinal growth trajectories in cohort studies. BMC Med Res Methodol. Mar 15 2022;22(1):68. doi: 10.1186/s12874-022-01542-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-022-01542-8</ArticleId><ArticleId IdType="pmc">PMC8925070</ArticleId><ArticleId IdType="pubmed">35291947</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs. Updated December
12, 2022. Accessed April 14, 2023, https://www.whocc.no/atc_ddd_index_and_guidelines/atc_ddd_index/</Citation></Reference><Reference><Citation>Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry. Dec 1991;48(12):1082&#x2013;8. doi: 10.1001/archpsyc.1991.01810360046007</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.1991.01810360046007</ArticleId><ArticleId IdType="pubmed">1845226</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar R, Joseph B, Pazdernik VM, et al. Real-World Clinical Practice Among Patients With Bipolar Disorder and Chronic Kidney Disease on Long-term Lithium Therapy. J Clin Psychopharmacol. Jan-Feb 01 2023;43(1):6&#x2013;11. doi: 10.1097/jcp.0000000000001632</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/jcp.0000000000001632</ArticleId><ArticleId IdType="pmc">PMC10590216</ArticleId><ArticleId IdType="pubmed">36584244</ArticleId></ArticleIdList></Reference><Reference><Citation>Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand. Sep 2001;104(3):163&#x2013;72. doi: 10.1034/j.1600-0447.2001.00464.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-0447.2001.00464.x</ArticleId><ArticleId IdType="pubmed">11531653</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanner C, Heerspink HJL, Zinman B, et al. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. J Am Soc Nephrol. Nov 2018;29(11):2755&#x2013;2769. doi: 10.1681/asn.2018010103</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/asn.2018010103</ArticleId><ArticleId IdType="pmc">PMC6218863</ArticleId><ArticleId IdType="pubmed">30314978</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong GP. Empagliflozin-Mediated Lithium Excretion: A Case Study and Clinical Applications. Am J Case Rep. Jun 10 2020;21:e923311. doi: 10.12659/ajcr.923311</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/ajcr.923311</ArticleId><ArticleId IdType="pmc">PMC7304652</ArticleId><ArticleId IdType="pubmed">32518219</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregg LP, Richardson PA, Nambi V, et al. Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Patients with CKD. J Am Soc Nephrol. Jan 1 2025;36(1):87&#x2013;98. doi: 10.1681/asn.0000000000000477</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/asn.0000000000000477</ArticleId><ArticleId IdType="pmc">PMC11706553</ArticleId><ArticleId IdType="pubmed">39186372</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik ME, Falkentoft AC, Jensen J, et al. Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021. Lancet Reg Health Eur. Jun 2023;29:100617. doi: 10.1016/j.lanepe.2023.100617</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2023.100617</ArticleId><ArticleId IdType="pmc">PMC10230617</ArticleId><ArticleId IdType="pubmed">37265783</ArticleId></ArticleIdList></Reference><Reference><Citation>Thewjitcharoen Y, Yenseung N, Malidaeng A, et al. Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center. Diabetol Metab Syndr. 2017;9:96. doi: 10.1186/s13098-017-0297-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13098-017-0297-y</ArticleId><ArticleId IdType="pmc">PMC5709980</ArticleId><ArticleId IdType="pubmed">29213337</ArticleId></ArticleIdList></Reference><Reference><Citation>Bak M, Chi SA, Jeon K, et al. Discontinuation rates, clinical effects and provocation factors of SGLT-2 inhibitor in the real world. Sci Rep. Dec 28 2024;14(1):30653. doi: 10.1038/s41598-024-71231-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-71231-7</ArticleId><ArticleId IdType="pmc">PMC11681096</ArticleId><ArticleId IdType="pubmed">39730335</ArticleId></ArticleIdList></Reference><Reference><Citation>Anttila V, Bulik-Sullivan B, Finucane HK, et al. Analysis of shared heritability in common disorders of the brain. Science. Jun 22 2018;360(6395)doi: 10.1126/science.aap8757</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aap8757</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans-Lacko SE, Zeber JE, Gonzalez JM, Olvera RL. Medical comorbidity among youth diagnosed with bipolar disorder in the United States. J Clin Psychiatry. Oct 2009;70(10):1461&#x2013;6. doi: 10.4088/JCP.08m04871</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.08m04871</ArticleId><ArticleId IdType="pubmed">19744408</ArticleId></ArticleIdList></Reference><Reference><Citation>Madden JM, Araujo-Lane C, Foxworth P, et al. Experiences of health care costs among people with employer-sponsored insurance and bipolar disorder. J Affect Disord. Feb 15 2021;281:41&#x2013;50. doi: 10.1016/j.jad.2020.10.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2020.10.033</ArticleId><ArticleId IdType="pubmed">33290926</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>